ATE and GUDOh I'm sure we'll be having some serious discussions about ATE before the end of 2023.
- GUD with 6% drug rights globally for any future ATE drug
- shelf prospectus was prepared for ATE's OTENA (now expired) - IMO - will it return? I'd bet so
- 3rd and final P2 trial for OTENA in Q4 ... very quick trial ?
- new formulation for OTENA is likely ready, manufacturing process modified and GMP pills should arrive any day now.
- PK/PD trial this summer on healthy candidates.
- DILIsym trial says acute formulation is liver-friendly.
- DILIsym to be used for chronic plan too.
- Not only do we prepare for P2-Acute with PK/PD ... we prep a chronic regimen with a worst-case sophisticated regimen control (low dose / high dose / no dose ... concoction ... as required). I'd even throw in Naproxen pills right into that sophisticated regimen control - but - that's the layman in me pretending that I could offer an infinite number of regimens to fit the chronic bill.
Strategy was chosen - 5/7 year patent was abandoned for 20 years.
Angry investors need not apply !
Patience required !!!
And that's how we play !!!!
Risky game - but - someone has to play ... or ... we wouldn't have a game. : )